Aima Diagnostics Benchmark: A New Standard for Evaluating Medical AI

Why Medical AI Needs a Consistent Quality Standard

In recent years, hundreds of artificial intelligence systems have emerged that can analyze blood test results. However, the industry continues to face a fundamental challenge: how can the quality of a new model version be assessed objectively?

In many cases, developers report improvements in selected metrics or evaluate their systems on limited datasets. Yet an algorithm update may introduce new errors, remove previously correct conclusions, or reduce performance in rare or complex clinical cases without these changes being immediately detected.
In software engineering, this problem has long been addressed through regression testing—a structured process used to confirm that new changes have not degraded previously functioning capabilities.
We believe that medical AI should be developed according to the same principle, but with substantially more rigorous requirements.

The Aima Diagnostics Benchmark
AIMA Diagnostics is developing a proprietary Benchmark—a standardized evaluation framework for assessing the quality of artificial intelligence models used to interpret blood test results.
The purpose of the Benchmark is to provide reproducible, objective, and consistent quality assessment for every new model version.
Before release, each model update is tested against a fixed set of reference clinical cases known as the Golden Dataset.

This approach makes it possible not only to measure model improvement, but also to identify any deterioration in performance at an early stage.

The Golden Dataset
At the core of the Benchmark is a continuously expanding library of anonymized clinical cases.
Each case represents a complete clinical scenario and may include:

• laboratory test results;
• the patient’s age and sex;
• current medications;
• lifestyle factors;
• additional variables relevant to personalization;
• clinically validated conclusions.

This dataset serves as the reference standard against which every new version of the system is evaluated.

Evaluating More Than Accuracy
We believe that the quality of medical AI cannot be reduced to a single accuracy score.
The Benchmark therefore assesses multiple dimensions of model performance.
For each clinical case, the evaluation includes:

• the correctness of the primary interpretation;
• the completeness of identified pathological patterns;
• the ranking of the most likely clinical conditions;
• the quality and clarity of the clinical explanation;
• the appropriateness of recommendations for additional testing;
• the absence of false-positive conclusions;
• the absence of missed clinically significant abnormalities;
• the consistency of interpretation across model versions.

Regression Testing
Every model update automatically undergoes a complete evaluation cycle.
The new version is compared with the previous version for each individual clinical case.
If a conclusion that was previously correct becomes less accurate, less complete, or less clinically appropriate, the system records a regression.
This makes it possible to detect changes that would be extremely difficult to identify through conventional manual testing alone.
A similar approach is widely used in the development of safety-critical software systems. In our view, it should become a standard requirement for medical artificial intelligence.

A Library of Diseases and Clinical Conditions
The Benchmark covers a broad range of pathological conditions.
For each clinical area, different types of cases are developed, including:

• early-stage disease;
• typical presentations;
• severe forms;
• borderline findings;
• coexisting conditions;
• the effects of pharmacological treatment;
• changes in laboratory biomarkers over time.

This approach allows the model to be evaluated under conditions that more closely reflect real-world clinical practice.

Personalization as an Essential Part of Evaluation
One of the defining features of Aima Diagnostics is the depth of personalization applied to laboratory interpretation.
Identical laboratory values may have different clinical significance depending on the patient’s age, sex, medications, lifestyle, harmful habits, geographic region, and other individual factors.
The Benchmark therefore evaluates not only the model’s ability to recognize laboratory patterns, but also its ability to incorporate patient-specific context into the interpretation.

Evaluating Longitudinal Changes
In many diseases, a single blood test does not provide a complete clinical picture.
The Benchmark therefore includes scenarios in which the model analyzes a sequence of laboratory tests from the same patient.
This makes it possible to assess the system’s ability to identify:

• disease progression;
• response to treatment;
• changes in risk over time;
• clinically meaningful biomarker trends.

Independent Expert Review
An important part of the evaluation process is the comparison of model-generated conclusions with assessments made by independent physicians.
This approach helps measure the level of agreement between the system and medical experts. It also provides valuable evidence for the continued improvement of the underlying algorithms.

Why This Matters for the Entire Industry
The history of artificial intelligence shows that major technological advances often follow the introduction of widely accepted evaluation standards.
Computer vision had ImageNet.
Natural language processing introduced GLUE and SuperGLUE.
Large language models are assessed using specialized independent benchmarks.
We believe that the medical interpretation of laboratory data also requires a reproducible, transparent, and objective standard for quality evaluation.

Our Vision
We are developing the Aima Diagnostics Benchmark as a long-term quality assurance infrastructure for medical artificial intelligence.
Our goal is to ensure that every new model version demonstrates its quality not through declarations, but by successfully completing rigorous, standardized testing against reference clinical cases.
We believe that the advancement of medical AI must be based not only on innovation, but also on systematic quality assessment, reproducibility of results, and transparency of the evaluation process.
These principles can help strengthen trust in medical artificial intelligence among physicians, laboratories, research organizations, and patients.


Aima Diagnostics Perspective
By the AIMA Diagnostics Research and Clinical Validation Team

This article outlines vision for a reproducible, clinically grounded, and transparent standard for evaluating medical AI systems used to interpret laboratory data.

Published: 19.07.2026